Meningococcal vaccine - XenovaAlternative Names: MEN-B; Meningitis vaccine - Xenova
Latest Information Update: 29 Jul 2004
At a glance
- Originator Xenova Group
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Meningococcal infections